Successful treatment of cerebral hemorrhage using computed tomography angiography in a patient with left-ventricular-assist device

Morito, Haruna; Nishimura, Takashi; Ando, Masahiko; Katoh, Osamu; Hisagi, Motoyuki; Imai, Hideki; Iijima, Akira; Motomura, Noboru; Kyo, Shunei; Ōno, Minoru

doi:10.1007/s10047-011-0608-2

Cited by 6 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hypotension 8 Right heart failure Bleeding (early and late) [10][11][12] Infection [13][14][15][16][17][18] Thromboembolism 11,19 Thrombosis of the device 11 GI bleeding (including acquired von Willebrand syndrome and AV malformation with continuous flow devices) 11,[20][21][22][23][24][25] Arrhythmias [26][27][28][29] Thoracic effusion (pleural and pericardial serous and blood) 30 Neurologic complications (ischemic, hemorrhagic strokes, TIAs, seizures, etc) 11,[31][32][33][34][35][36] Thrombosis or fusion aortic valve 37,38 Renal failure 39 Device failure (driveline, battery/power failure, mechanical) 8…”

Section: Postdischarge Complications Associated With Vads 89mentioning

confidence: 99%

Management of Patients With Implanted Ventricular Assist Devices for Noncardiac Surgery

Hessel

2013

Semin Cardiothorac Vasc Anesth

View full text Add to dashboard Cite

The latest report (fifth report, 2013) of the Interagency Registry for Mechanical Assist Circulatory Support (INTERMACS) reported that since June 2006, 6561 adult patients had received primary implants of left ventricular assist devices (LVADs). 1 Of the devices, 136 were total artificial hearts, 901 were pulsatile devices, and 5515 were continuous flow (CF) devices, of which 5366 involved isolated LVAD implantations. Of the 6561 implants, 4644 were implanted as bridges to heart transplantation (BTT) and 1834 (28%) as destination therapy (DT); however in 2012, 44% of these were implanted for DT. Patients with CF devices had fewer complications and better survival than those with pulsatile devices. Since 2010, essentially 100% of patients stratified to DT received CF devices. Actuarial survival of all patients with CF devices is 80% at 1 year, 70% at 2 years, 59% at 3 years, and 47% at 4 years. Lietz et al 2 reported their later results with the Heart Mate XVE device after the REMATCH trial, and John et al, 3 Loforte et al, 4 and Slaughter et al 5 reported early results with the HeartMate II. More recently, John et al 6 and Adamson et al 7 reported their results with HeartMate II devices implanted in 130 and 55 patients, respectively, between 2005 and 2010. Adverse events included bleeding (requiring red blood cells or reexploration, at time of initial implantation or late gastrointestinal [GI] bleeding [~18%]) in 15% to 36%, infection (local, device and driveline related, or sepsis) in 25% to 50%, neurologic events (ischemic or hemorrhagic strokes or other events) in 10% to 20%, right ventricular (RV) failure in 3% to 5%, and renal failure in 2% to 3%. Device failure or malfunction or thrombosis was infrequent (Table 1). Early deaths were related to multi-organ failure, respiratory failure, RV failure, sepsis, hemorrhage, neurologic events, device thrombosis, and withdrawal. Kirklin and colleagues 40 have summarized the incidence of adverse events during the first 12 months following implantation of CF devices for DT in 1160 patients in the INTERMACS registry (Table 2). Adamson et al 7 did not find significant difference in outcome of the 20 patients over 70 years of age at time of implantation compared with 25 patients under 70 years of age. Kirklin et al presented data that suggest that in lowrisk patients (ie, those without biventricular support, previous cancer, cardiogenic shock, severe RV failure, blood urea nitrogen >50, age >70, and body mass index >32) CF 506788S CVXXX10.

show abstract

Section: Postdischarge Complications Associated With Vads 89mentioning

confidence: 99%

Management of Patients With Implanted Ventricular Assist Devices for Noncardiac Surgery

Hessel

2013

Semin Cardiothorac Vasc Anesth

View full text Add to dashboard Cite

show abstract

Endovascular treatment of cerebral hemorrhage in a patient with a left ventricular assist device: report of a case

et al. 2013

View full text Add to dashboard Cite

Cerebral hemorrhage is a common lethal complication associated with left ventricular assist device (LVAD) management. We performed cerebral angiography on patients with LVAD who developed cerebral hemorrhage and determined that ruptured aneurysms were the cause in some cases. Endovascular management of patients with LVAD can be a therapeutically useful approach for cerebral hemorrhage caused by aneurysm rupture.

show abstract

Journal of Artificial Organs 2012: the year in review

et al. 2013

View full text Add to dashboard Cite

Successful treatment of cerebral hemorrhage using computed tomography angiography in a patient with left-ventricular-assist device

Cited by 6 publications

References 10 publications

Management of Patients With Implanted Ventricular Assist Devices for Noncardiac Surgery

Management of Patients With Implanted Ventricular Assist Devices for Noncardiac Surgery

Endovascular treatment of cerebral hemorrhage in a patient with a left ventricular assist device: report of a case

Journal of Artificial Organs 2012: the year in review

Contact Info

Product

Resources

About